Related Experiment Video
Updated: Mar 29, 2026
08:49
Models of Bone Metastasis
Published on: September 4, 2012
43.4K
[Pharmacological Treatment for Bone Metastasis]
Shigeo Yamaguchi1, Shunichiro Kageyama, Kayo Miura
1Dept. of Medical Oncology, Juntendo University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 26, 2015
Summary
New guidelines recommend aggressive use of bone modifying agents (BMA) to treat bone metastasis in various cancers, improving outcomes and reducing skeletal related events (SRE). This approach is vital for enhancing patient survival and quality of life.
Area of Science:
- Oncology
- Pharmacology
- Bone Biology
Context:
- Bone metastasis significantly impacts cancer patient outcomes across multiple cancer types.
- Recent evidence-based guidelines for diagnosing and treating bone metastasis have been published.
- Cancer cells disrupt bone remodeling by inhibiting osteoblasts and promoting osteoclast activity.
Purpose:
- To summarize evidence-based guidelines for the pharmacological treatment of bone metastasis.
- To highlight the role of bone modifying agents (BMA) in managing cancer-related bone complications.
- To inform clinical practice regarding the use of BMA for specific cancer types.
Summary:
- Guidelines recommend bone modifying agents (BMA) for treating bone metastasis in lung, breast, prostate cancers, and multiple myeloma.
- BMA are effective in suppressing skeletal-related events (SRE) in common solid tumors.
- For multiple myeloma, BMA demonstrate efficacy in improving overall survival alongside SRE suppression.
Impact:
- Promotes aggressive pharmacological intervention for bone metastasis.
- Aims to improve treatment outcomes and reduce morbidity associated with bone metastasis.
- Supports evidence-based decision-making for oncologists and healthcare providers treating bone metastasis.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:40Bone Remodeling
41.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.1K
01:15Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
01:31Osteoclasts in Bone Remodeling
4.7K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
818
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
818
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.1K